Semaglutide Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: Semaglutide evidence and protocol review

Metabolic Research peptide Injection solutionTabletLyophilized research material needs_revision Best effort · source review pending

Also known as: Ozempic, Wegovy, Rybelsus, GLP-1 RA

Open in Calculator ← Compound Index All Tools

Best-effort research profile: this record has not passed full two-source scientific verification. Descriptive fields, research protocols, storage/handling notes, and interaction guidance below are shown with their evidence labels, but calculator presets and exact dosing math remain hidden until the record is verified or reaches Community-Supported status.

Quick Facts

Reference Sizes

0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg labeled weekly injection doses, 7.2 mg current adult maximum for selected weight-reduction use, 5 mg RUO vial

Storage

Refrigerate 2-8 deg C before first use; room-temperature window after first use per product labeling - verify against current FDA label.

Solubility

Form, salt, and formulation dependent; verify the lot-specific COA

Best-Effort Research Profile

Semaglutide is a long-acting GLP-1 receptor agonist (~94% homology to human GLP-1, modified for a ~7-day half-life via fatty-acid acylation and albumin binding, enabling weekly SC dosing). The STEP 1 trial (NEJM; ClinicalTrials.gov NCT03548935) reported a 14.9% mean body-weight reduction at 68 weeks in adults with overweight/obesity versus 2.4% with placebo. The SELECT cardiovascular-outcomes trial (N=17,604) reported a 20% relative reduction in major adverse cardiovascular events (MACE) in patients with overweight/obesity and established cardiovascular disease. Approved formulations: Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management.

Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.

Research Profile

Half-Life

~7 days (enables once-weekly dosing)

Onset

Gradual appetite/glycemic effect over 4-8 weeks as dose is titrated

Administration Routes (Research)

Subcutaneous (SC)

Reported Research Effects

Reduces HbA1c and fasting glucose (glucose-dependent insulin secretion)
Suppresses appetite via central satiety pathways
Slows gastric emptying
Reduces major adverse cardiovascular events (SELECT trial)

Reported Research Side Effects

Human safety, pharmacokinetics, and interaction data are incomplete

Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Route-Specific Research Protocols

Amounts and schedules are separated by administration route. Evidence badges distinguish labels, human studies, preclinical work, community reports, and evidence gaps.

Label / guideline Human study Community only Preclinical only Not established

Subcutaneous (SC) Label / guideline

Weeks 1-4: 0.25 mg weekly; weeks 5-8: 0.5 mg; weeks 9-12: 1 mg; weeks 13-16: 1.7 mg; week 17 onward: 1.7 or 2.4 mg maintenance depending on indication and tolerability

Frequency / timing: Weekly
Duration / setting: 16-week label escalation then maintenance
Technique: SC
Evidence: Regulatory label

Context: current WEGOVY prescribing information

Formulation: Route-specific sterile formulation and professional handling requirements apply; concentration cannot be inferred from an oral or topical product.

Route safety: Use only in the cited label or guideline context; route, formulation, indication, and patient-specific limits still apply.

Source 1

Subcutaneous (SC) Label / guideline

For selected adults who tolerate 2.4 mg for at least 4 weeks and need additional weight reduction, the current label permits escalation to 7.2 mg once weekly

Frequency / timing: Weekly
Duration / setting: Label-directed after established 2.4 mg tolerance
Technique: SC
Evidence: Regulatory label

Context: current WEGOVY prescribing information

Formulation: Route-specific sterile formulation and professional handling requirements apply; concentration cannot be inferred from an oral or topical product.

Route safety: Use only in the cited label or guideline context; route, formulation, indication, and patient-specific limits still apply.

Source 1

Do not convert an amount between routes. Bioavailability, formulation, sterility, monitoring, and clinical context differ by route. Research-use context only; independently verify every cited source.

Research Notes

A 5 mg lyophilized vial is not an FDA-approved semaglutide presentation. The current WEGOVY label includes injection and tablet presentations and permits 7.2 mg weekly only in the specific labeled adult setting after at least four weeks at 2.4 mg; Ozempic and other semaglutide products have different indications and dosing.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources Under Review

WEGOVY semaglutide prescribing information — DailyMed (NIH)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.